Shrier Wealth Management’s AbbVie ABBV Stock Holding History

Shrier Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$755K	Hold	3,001	–	–	0.25%	75
2026 Q1	$653K	Sell	3,001 -10	-0.3%	-$2.22K	0.24%	79
2025 Q4	$688K	Buy	+3,011	New	+$686K	0.27%	75

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Shrier Wealth Management's ABBV Position: Q2 2026 in Review

Shrier Wealth Management held its AbbVie (ABBV) position steady in Q2 2026 at 3,001 shares worth $755K. The position accounts for 0.25% of the portfolio, ranked #75.

Shrier Wealth Management first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Shrier Wealth Management held 3,001 shares of AbbVie worth $755K as of Q2 2026.
Shrier Wealth Management left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.25% of Shrier Wealth Management's portfolio in Q2 2026, its #75 holding.
Shrier Wealth Management first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Shrier Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.